Novo Nordisk updates DKK 9.3bn share buyback

Novo Nordisk details recent buyback activity, now holding 1.1% of its 4.47 billion shares as treasury stock under a DKK 15 billion programme.

Rhea-AI Filing Summary

Novo Nordisk A/S (NVO) reports progress on its ongoing B share repurchase programme conducted under EU Safe Harbour Rules. The programme, which began on May 6, 2026, permits repurchases of B shares for up to DKK 11,200,000,010.45 through February 1, 2027, as part of a broader 12‑month share repurchase plan of up to DKK 15 billion starting February 4, 2026.

Between September 7 and September 11, 2026, the company repurchased 1,050,000 B shares at daily average prices between DKK 278.62 and DKK 297.98, bringing total repurchases under the May programme to 18,325,000 B shares and total repurchases since February 4, 2026 to 33,084,179 B shares at an average price of DKK 281.89, equal to DKK 9,326,186,478. Novo Nordisk now holds 47,124,876 B shares as treasury shares, corresponding to 1.1% of its 4,465,000,000 total A and B shares.

Key Figures

Overall repurchase capacity: DKK 15,000,000,000 May 6, 2026 programme size: DKK 11,200,000,010.45 Recent weekly repurchases: 1,050,000 shares +5 more

8 metrics

Overall repurchase capacity DKK 15,000,000,000 Planned B share repurchases during 12‑month period beginning February 4, 2026

May 6, 2026 programme size DKK 11,200,000,010.45 Maximum B shares to be repurchased from May 6, 2026 to February 1, 2027

Recent weekly repurchases 1,050,000 shares B shares bought between September 7 and 11, 2026

Cumulative repurchases since Feb. 4, 2026 33,084,179 shares Total B shares repurchased as of September 11, 2026

Average repurchase price DKK 281.89 per share Average price for 33,084,179 B shares repurchased since February 4, 2026

Total repurchase value DKK 9,326,186,478 Value of B shares repurchased since February 4, 2026

Treasury shares held 47,124,876 shares B shares held as treasury shares after the reported transactions

Treasury share percentage 1.1% Treasury B shares as a percentage of total share capital

Key Terms

share repurchase programme, treasury shares, Safe Harbour Rules, ADR, +1 more

5 terms

share repurchase programme financial

"Novo Nordisk initiated a share repurchase programme in accordance with Article 5"

A share repurchase programme is a company's plan to buy back its own shares from the market. This reduces the total number of shares available, which can increase the value of remaining shares and signal confidence in the company's health. For investors, it can indicate that the company believes its stock is undervalued and may lead to higher share prices.

treasury shares financial

"Novo Nordisk owns a total of 47,124,876 B shares of DKK 0.10 as treasury shares"

Treasury shares are a company’s own stock that it has repurchased and keeps on its books instead of canceling or leaving in the hands of outside investors. Think of them like coupons a business puts back in a drawer: they don’t vote or receive dividends while held, but they can be reissued later for employee pay or fundraising. For investors this matters because buybacks change the number of shares that count toward earnings and ownership, can boost per‑share metrics, and use corporate cash that might otherwise go to growth or dividends.

Safe Harbour Rules regulatory

"in accordance with ... 2016/1052 of 8 March 2016 (the "Safe Harbour Rules")"

ADR financial

"Its ADRs are listed on the New York Stock Exchange (NVO)"

An American Depositary Receipt (ADR) is a financial certificate that lets investors buy shares of a foreign company through U.S. stock markets, similar to buying a local wrapper that represents the underlying foreign shares. ADRs matter because they make investing in overseas companies easier and more liquid by trading in U.S. dollars and under U.S. market rules, while still carrying currency, regulatory, and country-specific risks that can affect share value.

foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What share repurchase programme is Novo Nordisk (NVO) currently executing?

Novo Nordisk is executing a B share repurchase programme under EU Safe Harbour Rules, allowing purchases of up to DKK 11,200,000,010.45 from May 6, 2026 to February 1, 2027. This is part of an overall 12‑month repurchase plan of up to DKK 15 billion starting February 4, 2026.

How many Novo Nordisk (NVO) shares were recently repurchased and at what prices?

From September 7–11, 2026, Novo Nordisk repurchased 1,050,000 B shares (210,000 per day) at average prices between DKK 278.62 and DKK 297.98 per share, with individual daily transaction values ranging from about DKK 58.5 million to DKK 62.6 million.

What is the total amount Novo Nordisk (NVO) has repurchased since February 4, 2026?

As of September 11, 2026, Novo Nordisk has repurchased a total of 33,084,179 B shares since February 4, 2026 at an average price of DKK 281.89 per B share, corresponding to a total transaction value of DKK 9,326,186,478.

How many Novo Nordisk (NVO) shares are held as treasury shares now?

Novo Nordisk holds 47,124,876 B shares of DKK 0.10 as treasury shares, corresponding to 1.1% of the company’s total share capital. The total number of A and B shares outstanding, including treasury shares, is 4,465,000,000.

What is the total share capital of Novo Nordisk (NVO)?

The total share capital of Novo Nordisk consists of 4,465,000,000 A and B shares, including treasury shares. Within this total, the company currently holds 47,124,876 B shares as treasury shares, which is 1.1% of the share capital.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 06:06 AM Accepted by SEC EDGAR 09/15/2026 - 06:00 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________

FORM 6-K

________________

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

September 14, 2026

________________

NOVO NORDISK A/S

 (Exact name of Registrant as specified in its charter)

Novo Allé 1

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒           Form 40-F ☐

 

 

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 14 September 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.

Since the announcement 07 September, the following transactions have been made:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	17,275,000		5,221,774,293
7 September 2026	210,000	297.98	62,576,264
8 September 2026	210,000	295.53	62,062,090
9 September 2026	210,000	289.37	60,767,699
10 September 2026	210,000	288.08	60,496,529
11 September 2026	210,000	278.62	58,509,613
Accumulated under the programme	18,325,000		5,526,186,488

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 47,124,876 B shares of DKK 0.10 as treasury shares, corresponding to 1.1% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Page 2 of 2

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 11 September 2026, Novo Nordisk has since 4 February 2026 repurchased a total 33,084,179 B shares at an average share price of DKK 281.89 per B share equal to a transaction value of DKK 9,326,186,478.

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Novo Nordisk Media:
Ambre James-Brown	Liz Skrbkova (US)
+45 3079 9289	+1 609 917 0632
globalmedia@novonordisk.com	USMediaRelations@novonordisk.com
Novo Nordisk Investors:
Michael Novod	Sina Meyer
+45 3075 6050	+45 3079 6656
nvno@novonordisk.com	azey@novonordisk.com

Christoffer Togo Solgaard-Tullin
+45 3079 1471
cftu@novonordisk.com
Ida Schaap Melvold	Mads Berner Bruun
+45 3077 5649	+45 3075 2936
idmg@novonordisk.com	mbbz@novonordisk.com
Frederik Taylor Pitter (US)	Alex Bruce (US)
+1 609 613 0568	+1 640 230 0276
fptr@novonordisk.com	axeu@novonordisk.com

Novo Nordisk A/S Investor Relations	Novo Allé 1 2880 Bagsværd Denmark	Telephone: +45 4444 8888	www.novonordisk.com CVR no: 24 25 67 90
			Company announcement No 55 / 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: September 14, 2026   NOVO NORDISK A/S   Maziar Mike Doustdar Chief Executive Officer